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A REPORT FROM THE FORUM SESSION

Implementing the Medicare
Prescription Drug Benefit:
Continuing Challenges for States
Lee Partridge, Consultant
OVERVIEW — This National Health Policy Forum Meeting Report provides an overview and discussion of a technical session that took place on
July 12, 2005. The meeting was designed to re-visit issues discussed at a
similar meeting in July 2004, which was intended to offer a state perspective
on the implementation of the Medicare Prescription Drug, Improvement,
and Modernization Act (MMA) of 2003 and the new Medicare prescription
drug benefit. This report provides an update on the implementation issues
identified in 2004—including outreach, education and enrollment; coordination of care for individuals who are “dually eligible” for Medicare and
Medicaid; and the cost burden of the new program on states—and highlights
new issues that have since emerged. Observations and recommendations from
the panel are also included.
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A REPORT FROM THE FORUM SESSION:

Implementing the Medicare
Prescription Drug Benefit:
Continuing Challenges for States

On January 1, 2006, the new Medicare prescription drug benefit will become available to 43 million Medicare beneficiaries. In order to access this
new benefit, Medicare beneficiaries must first decide whether they want to
enroll in the new program and then must elect the prescription drug plan
they wish to join. This process will take place between November 2005 and
May 2006. In addition, for an estimated one in three Medicare beneficiaries
(14 million), Congress has authorized special financial assistance in the form
of a federal low-income subsidy (LIS)1 to help individuals with the cost of
the new benefit. Congress also granted most of these beneficiaries a special
benefit package that permits them to enjoy uninterrupted drug coverage
with no gaps and only very modest co-payments.2 Like their more affluent
peers, beneficiaries receiving the LIS assistance must also elect which drug
plan they wish to join, with the exception of individuals dually eligible for
Medicare and Medicaid. Those who are already receiving drug benefits in
a state Medicaid program (the “full benefit dual eligibles”) will be automatically assigned to a drug plan if they do not choose a plan on their own
before January 1, 2006.
As of December 31, 2005, states will no longer be able to receive federal
matching funds for prescription drug expenditures, which will officially
end Medicaid prescription drug coverage for dual eligibles. If they choose,
these beneficiaries will receive their medications through the Medicare
program instead. Federal matching funds will continue to be available
to states that elect to cover over-the-counter medications, as well as other
prescription drugs, such as benzodiasipines, that are not covered under
the Medicare benefit.
Implementation of the Medicare Prescription Drug, Improvement, and
Modernization Act (MMA) of 2003 poses a number of challenges for
states. In July 2004 the National Health Policy Forum held a technical
briefing session to identify and discuss those challenges. The discussion that day was subsequently summarized in a Forum report issued
on August 31, 2004.3 At that early date, the full scope and nature of
many implementation issues were unclear. The federal regulations had
not yet been published, and the outreach and education campaigns that
the Department of Health and Human Services and the Social Security
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Administration (SSA) would launch were in formulation. States were
just shaping their own proposals and budget estimates in preparation
for state legislative sessions in the winter of 2005. Many of the state decisions were dependent on the outcome of the federal decision-making
process. Consequently, on July 12, 2005, the Forum convened a second
discussion to provide an update on MMA implementation and to highlight new issues that emerged in the interim.
By July 2005, many of the questions that were raised in July 2004 had
been resolved. Some were, however, still open, and other new issues had
surfaced. To revisit and discuss these new and still unresolved issues,
the Forum invited three state Medicaid officials—Mike Fogarty from
Oklahoma, Carol Herrmann from Alabama, and Carolyn Ingram from
New Mexico—to participate in this follow-up technical session. They were
joined by federal staff, consumer advocates, Medicaid experts and researchers, and the senior official of a health plan that currently enrolls
both Medicare and Medicaid beneficiaries. The dialogue provided valuable insight into current activities and policy concerns from the state perspective. Like the 2004 meeting, the July 2005 session was deliberately
limited in size in order to permit in-depth discussion; therefore, the principal issues raised are summarized in this report for the benefit of our
wider audience. A list of all the Forum participants appears in the final
section of this report (see Appendix 2).
The intent of this report is to provide a current perspective on the multiple opportunities and potential barriers involved in implementing the
Medicare prescription drug benefit. It is hoped that the panelists’ observations will provide a better understanding of these issues and inform state and federal officials about potential problems, so that efforts
can be made to resolve them. The observations and recommendations
are a summary of points made by participants during the technical session. As always, the National Health Policy Forum hopes that this material will inform the broader policy discussion and will be helpful to
beneficiaries, advocates, researchers, and other stakeholders by providing them with a richer appreciation of the challenges ahead.
Three main areas of concern emerged during the discussion:
■

The daunting challenge of reaching, educating and enrolling the
potentially eligible LIS beneficiaries not currently enrolled in any
state Medicaid or prescription drug assistance program.

■

The need to ensure effective coordination of care among Medicaid,
Medicare, and private plans with regard to the dual eligibles.

■

The cost burden to the states of the new prescription drug benefit,
including the equity of the “clawback” payment.

The details of these concerns are provided in this report.
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EDUCATION, ENROLLMENT, AND OUTREACH
Participants commended the federal agencies’ energetic efforts with regard to reaching out to and educating beneficiaries about the new program. The Social Security Administration has a massive targeted mailing effort underway, sending program information and application forms
to over 15 million potential LIS beneficiaries. SSA has directed its field
staff to take advantage of community forums, health fairs, and other venues where potential beneficiaries might gather in order to explain the
new benefit. The Administration on Aging has provided new funding
and training opportunities and has suggested educational materials for
its state and local agency grantees. The
2006 edition of the CMS Medicare and The Social Security Administration (SSA) has a
You annual handbook, which will be massive targeted mailing effort underway, sendmailed to each Medicare household in
ing program information and application forms
October 2005, has been revamped to foto over 15 million potential LIS beneficiaries.
cus on the prescription drug benefit.
In addition, CMS has extensively upgraded its Web site and telephone
assistance capacity and has dedicated staff to work with many professional medical provider organizations as well as advocacy groups to help
those organizations inform their membership. Providers, especially the
physicians, pharmacists, health plans, and long-term care professionals
who currently serve dual eligibles, need to be educated about the changes.
States have also undertaken their own education activities, independent
of the federal agencies. They have done special mailings, spoken at meetings of state and local chapters of provider organizations, and organized
statewide implementation taskforces. No one underestimates the magnitude of this undertaking.

Medicare Plan Selection for Dual Eligibles
To minimize the impact of the change in Medicaid drug coverage for
dual eligibles, the federal government has decided it will automatically
enroll them in a drug plan in the fall of 2005. First, CMS will match Medicare enrollment data with state data (as of July 2005) for full benefit dual
eligibles. CMS will use this information to develop a pool of beneficiaries who are not currently enrolled in a Medicare Advantage Plan. In late
September 2005, after all the Medicare Prescription Drug Plan (PDP) contracts are final, CMS will autoenroll those beneficiaries (effective January 1, 2006) in a PDP that serves their region. Individuals who were already enrolled in a Medicare Advantage plan will be autoenrolled in
that plan for their prescription drug coverage. Both beneficiaries and
states will be notified of the plan assignments in late October 2005.
However, because the time frame for the autoenrollment and notification
process is so short, session participants noted there is a real question about
the ability of states, plans, and the federal agencies to share enrollment
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information accurately and promptly to avoid confusion. If a beneficiary
finds himself in a plan that is not his preferred choice, he or she may switch,
but each party needs to know about this possibility, and the process that
must be followed to complete this switch must be clearly communicated
and understood.
Informing beneficiaries about their right to switch plans poses a special
problem for Medicare beneficiaries who are already members of a Medicare Advantage health plan. Because all Medicare Advantage plans will
offer a prescription drug benefit, the beneficiary’s logical choice, and the
one the plans hope they will make, is to elect to stay with their current
MA plan. Should they elect another drug plan, however, the beneficiary
will be disenrolled from the MA plan and put back in the Medicare feefor-service market for all of their Medicare benefits. Plans are making
special efforts to inform their members about this possibility and explain
what action they must take to keep their current coverage.
One concern that was raised involves subsidization of the Medicare drug
benefit monthly premium. The law authorizes a premium subsidy only
up to the amount of the “regional LIS benchmark,” which is the average
cost in that region of a standard prescription drug benefit package. Patient
advocates have expressed concern that this limitation might place some of
the existing Medicare Advantage plans out of reach for some beneficiaries, including beneficiaries currently enrolled in those plans. The health
plan representative on the panel allayed that concern, however, by reporting that most of the plans believe they will be able to offer at least one
prescription drug package (many of the MA plans offer several Medicare
benefit packages) that will meet the LIS benchmark requirement.

Outreach
One major task facing all the organizations involved in implementing
the drug benefit is reaching the millions of individuals who are not currently enrolled in the Medicaid program as either a full benefit dual
eligible or a Medicare Savings Program (MSP) beneficiary,4 but may be
eligible for the new drug subsidy and enhanced drug benefit. These are
the individuals whose incomes are below 150 percent of the federal poverty level (FPL) and who have assets in excess of a certain dollar amount
($10,000 per individual or $20,000 per couple, in 2005). Some of these
potential beneficiaries are probably known to states because of enrollment in a state-funded pharmacy assistance program, where they exist,
and states will encourage these individuals to apply for LIS assistance.
Many, however, have never come forward to apply for any assistance
and have proved a difficult population to reach.5
Panelists noted that their outreach concerns are heightened by the fact
that a beneficiary’s failure to choose a plan when first eligible can result in
a financial penalty in the form of a higher monthly premium for individuals who enroll in a drug plan after the deadline of May 2006.6 Due to the

National Health Policy Forum | www.nhpf.org

5

Meeting Report
September 22, 2005

time constraints for educating and enrolling everyone—LIS beneficiaries
and non-LIS beneficiaries—there is grave concern that potential LIS beneficiaries will not get the outreach and education needed. As one state
official said, “This is the group that is most likely to have no help now to
get needed drugs. They should be our first priority.”

MSP Versus LIS: Making Sense of the Rules
One of the major points of confusion for beneficiaries may be that the
MSP and LIS programs have similar but not identical eligibility requirements. The MMA allows individuals to submit an application for the LIS
through either the SSA or the state Medicaid eligibility office. If they apply through SSA, that agency will review the application and make the
LIS program eligibility determination. In addition, SSA will forward limited information about the applicants to the state so that the Medicaid
agency can screen them for possible MSP eligibility. Persons applying at
a state Medicaid office will be screened for Medicaid
and/or MSP eligibility, and, if eligible, will automati- The decision on whether a person recally be deemed eligible for the LIS. If found ineli- ceives the LIS could depend on their
gible for Medicaid or an MSP, applicants will be
state of residence and on the agency
encouraged to fill out the SSA’s LIS application form,
which the state will forward to the SSA for decision. through which he or she applies.
In most states, the eligibility requirements for a MSP are different from
those being used by SSA for the LIS program, so persons found eligible
for either the MSP or the LIS benefits may not necessarily qualify for the
other. Although the majority of states have less restrictive eligibility rules
for MSPs than the LIS requirements, in some states the MSP rules are
stricter than those for the LIS.7 Federal regulations specify that persons
meeting a state’s eligibility criteria for Medicaid or its MSP are also entitled to the full LIS. Thus, the decision on whether a person receives the
LIS could depend on his or her state of residence and on the agency
through which he or she applies. For example:
■ States with more restrictive MSP rules. Arkansas, New Jersey, and

Ohio use the supplemental security income (SSI) asset rules to determine eligibility for their MSPs; the LIS asset limit is higher. In states
such as these, persons could be found ineligible for MSP but still qualify
for the LIS.
■ State with less restrictive MSP rules. In five states—Alabama, Ari-

zona, Delaware, Mississippi, and Minnesota—there is no asset limit
for the MSP program. In these states, persons found eligible for the
MSP would automatically qualify for the LIS. Some states use rules
different from those of the LIS program regarding countable income.
Indiana, for example, excludes in-kind support and maintenance; the
LIS rules do not.
Federal officials are encouraging potential beneficiaries to use the SSA
process because it is designed to be streamlined and user-friendly and
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can be done by telephone, internet, or direct mail, as well as in person. In
the less restrictive states, however, applying through SSA under the LIS
rules would result in a denial of LIS eligibility, whereas applying through
the state Medicaid agency would result in LIS approval due to the federal deeming provisions. It is important that “helper” organizations, including state and federal staff, be knowledgeable about these differences
as they craft their information and assistance efforts.

An overarching challenge will be to coordinate care among
three different entities: Medicaid, Medicare, and private plans.

CARE COORDINATION
Full Medicaid benefit dual eligibles and, to a lesser degree, state MSP beneficiaries often have multiple medical conditions and take multiple medications. Many are on “maintenance regimens,” meaning they must take
certain medications daily or weekly in order to avoid acute care episodes
or maintain physical mobility. Session participants, therefore, raised a number of issues concerning possible barriers to the effective coordination of
care, both during the transition from Medicaid to Medicare coverage and
after the beneficiaries are successfully enrolled in a Medicare plan.

Transition Issues
Panelists identified a host of transition issues. First was the obvious concern about effective transition for dual eligibles from the Medicaid program to a Medicare drug plan, in order to minimize any disruption in
care. Beneficiaries or their surrogates, their primary care providers, and
their pharmacists need to know the exception and appeal process that
can be used if the Medicare plan’s formulary does not include the drug
the individual is currently taking. There must be a method for resolving
mechanical problems, such as delays in receipt of the Medicare plan’s
enrollment identification card and inability to refill a prescription. Finally, if the state has decided to cover drugs excluded from the Medicare
benefit package, like benzodiasipines, beneficiaries and providers need
to know of those decisions rather than assume these drugs will no longer
be available to the beneficiary after January 1, 2006.

Sharing Drug Utilization Data
Meeting participants agreed that an overarching challenge will be to coordinate care among three different entities—Medicaid, Medicare, and
private plans—in a manner that ensures beneficiaries’ timely access to
appropriate care. A key element in effective care management is ready
access to data regarding beneficiary drug utilization. Under the federal
regulations, the drug plans must submit this information to CMS but are
not required to share it with the states for dual eligibles, even though the
state may be providing long-term or acute care coverage for many of
these individuals. As a result, the state may be unaware of a significant
change in a person’s condition. Conversely, if an individual is taking a
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drug that is not covered under the Medicare plan but is covered under
the state Medicaid program, there should be a route for that data to be
shared with the Medicare plan and/or Medicare primary care provider
in order to avoid adverse drug interactions.
Finally, participants observed that lack of access can also hamper state
fraud and abuse efforts, as a potentially significant amount of data that
would help flag aberrant provider or recipient patterns could be lost.

Integration with Medicare Advantage Special Needs Plans
The MMA authorized a new type of Medicare Advantage plan, the Special
Needs Plan (SNP), which can directly target dual eligibles for enrollment.
This new type of plan has the potential to improve care coordination between the Medicare and Medicaid programs. New Mexico, for example, is
in the process of implementing mandatory enrollment of its dual eligibles
in managed care. The state is keenly interested in the possibility of enrolling them in Medicare SNPs, because doing so would place the locus of
care coordination among acute and long-term care, as well as prescription
drugs, within the same entity. Panelists pointed out that the effectiveness
of the new plans may be hampered by the fact that Medicare and Medicaid managed care providers operate under different federal and state rules,
which can lead to inefficiencies and confusion.

NEW STATE COSTS
Dual eligibles already are a very expensive segment of any state Medicaid population. They constitute the majority of users of nursing home
care and home- and community-based care. In addition, dual eligibles
account for more than half of the total Medicaid drug expenditures in
any year. Over one third of the dual eligibles are under age 65 and eligible because of permanent disability. Their drug costs can be especially
high, often due to heavy use of antipsychotic medications. Analysis of
1999 state Medicaid drug expenditure data done by Mathematica Policy
Research, Inc., showed that the average drug expenditure for the disabled dual eligible was almost 50 percent more than the average spent
for dual eligibles aged 65 and over.8 Total Medicaid expenditures for dual
eligibles in 1999 were $8.6 billion.

The Clawback Requirement
As Congress debated extending prescription drug coverage to all Medicare beneficiaries, it questioned whether the states should enjoy a fiscal
“windfall” if the burden of paying for drugs for dual eligibles moved entirely to the federal government. As a result, the MMA includes a provision that exacts a payment (known as the “clawback”) from the states for
each dually eligible beneficiary enrolled in the new Medicare program.
This raises serious fiscal and policy concerns for the states.
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The clawback formula uses 2003 as its base year in computing the average
per-state drug expenditure for the dual eligibles. In many states, policy
changes adopted in 2002 or 2003 have reduced that average dollar amount
below the 2003 level, especially if adjusted for inflation. Alabama, for example, has implemented a preferred drug list, a therapeutic alternative
formulary, and other initiatives that have altered its spending and saved
an estimated $116 million since 2003. None of those savings will be reflected in computing Alabama’s clawback payment. A similar pattern prevails in many other states, where the average inflation-adjusted per capita
cost for a dual eligible in 2006 could be below that of 2003.9
Counting dual eligibles — The clawback requirement may have the
unintended consequence of discouraging states from expanding or continuing optional full Medicaid benefit coverage for seniors and disabled
persons whose incomes fall between the mandatory coverage level and
100 percent of the FPL. That perverse incentive exists because another factor in the clawback formula will be the
state’s current enrollment of dual eligibles.
Dual Eligibles: A Case Study
If a state that today offers full Medicaid
eligibility up to 100 percent of the FPL
In an analysis done in Maryland using fiscal year 2004 data
elects to roll back that income ceiling or
on approximately 120,000 dual eligibles, the findings indieliminate the option altogether, it will recated a variety of inconsistencies. Although nearly 90 percent
duce the current enrollment of dual eliof the files were successfully matched, a significant number
gibles and, therefore, its total clawback
of dual eligibles were not appropriately counted. For example,
payment. Two states, Mississippi and MisCMS had Medicare IDs for a large number of Medicaid ensouri, have passed legislation that would
rollees that the state had not identified as dually eligible. Condo that. Several other states discussed the
versely, Maryland identified dual eligibles and has records
possibility during their 2005 legislative
showing the payment of Medicare Part B premium payments
sessions. Fiscal pressures may force more
to CMS on behalf of more than 1,000 beneficiaries for whom
states into a similar posture in coming
CMS had no record in their Medicare files. In some cases,
years, causing many seniors and indibeneficiaries were identified on both files, but their Medividuals with disabilities to lose access to
care ID numbers did not match.
Medicaid-funded services.
There are numerous state and national implications from this
State panelists also observed that there are
example. First, only those dual eligibles that are identified on
likely to be problems determining exactly
the state’s file will be autoenrolled in the Medicare prescripwho is and who is not a dual eligible, or
tion drug benefit. Second, the clawback payments will be caleven a current MSP enrollee. The accuracy
culated from inaccurate files, and states will continue to pay
will depend on the data matches between
incorrectly for prescription drugs (and other Medicaid serstate and federal files. Previous statevices) for many individuals who are dual eligibles but have
federal matches have frequently revealed
not been identified as such. Finally, it appears that Maryland
multiple problems, such as beneficiaries
has been paying some form of Medicare cost sharing for indiwith several Medicare identification numviduals who are not actually on Medicare. State and federal
bers over time, beneficiaries with differofficials are already working to try to improve the data
ing Medicare ID numbers on the state and
matches, but reconciling differences can often take considerfederal files, and beneficiaries identified
able staff time and effort, resources that are in short supply at
as Medicare recipients on a state or fedboth the state and federal levels.
eral file, but not both (see text box).
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State panelists urged further discussion with their federal partners not
only on the clawback formula itself but on the broader issue of whether
this state payment to the federal government is an appropriate policy as
currently configured.

The Woodwork Effect and Other Challenges
States will face, and are already incurring, other new costs due to the
new Medicare drug benefit. They must be prepared to handle a surge in
eligibility applications for both the LIS and MSPs. They must educate
beneficiaries and providers about the Medicaid change. They will need
to reprogram their claims payment, third-party liability, and eligibility
management information systems. Most
The MMA may result in savings to retirees,
critical of all, they must expect and budget
for increased caseloads in their Medicaid
but those savings will likely accrue to the
and MSPs if the outreach efforts are successpension funds, not to a state’s general fund
ful. Alabama, for example, estimates that its
or its Medicaid program.
MSP caseload will grow by 30 percent.
The total new costs for the states could be considerable. Some argue that
the MMA will result in savings in state health care costs for their retirees,
but state officials noted that often those savings will accrue to the pension funds themselves and will not be available to a state’s general fund
or its Medicaid program. Thus the savings may not help close the gap
between states’ current Medicaid budget projections and their anticipated
increased funding needs due to the Medicare drug benefit.

OBSERVATIONS AND RECOMMENDATIONS
Over the course of the discussion, several key recommendations emerged
for implementation of the new Medicare drug benefit, as well as postimplementation activities. Although not all participants concurred on
every recommendation, each point listed below garnered support from
at least two panel members at the meeting.
■ Delay the transition for dual eligibles. To minimize potential dis-

ruptions in care and access to prescription medications for this vulnerable population, the group recommended postponing the December 31, 2005, termination date for federal Medicaid prescription drug
coverage. Autoenrollment efforts could proceed, but the inevitable
problems that will surface during the transition would not impact continuing drug regimens if federal Medicaid matching funds continued
to be available for some limited period of time.
■ Postpone imposition of the late enrollment penalty. The Medi-

care Modernization Act should be amended so that the late enrollment penalty for the LIS population will be postponed beyond May
2006. Outreach to the potentially eligible beneficiaries not currently
known to the states or federal government through Medicaid and
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MSPs is probably the greatest enrollment challenge; many individuals
with incomes between 120 and 150 percent of the FPL, in particular,
will be missed. A delay would allow the federal agencies, states, and
community groups to focus on educating this vulnerable population
after the bulk of the Medicare beneficiary population has made its plan
decisions. In addition, these beneficiaries would not be penalized for
their late enrollment.
■ Make drug utilization data available to states. CMS should estab-

lish some mechanism that permits states’ continued access to the
Medicare drug utilization data. This would not only help improve
the coordination of care for duals but also bolster state efforts to control fraud and abuse.
■ Streamline managed care coordination. The different and sometimes

conflicting regulations governing Medicaid managed care plans and
Medicare Advantage plans should be reviewed with the intent of minimizing the resulting inefficiencies and confusion. This is particularly
true for the policies governing the new Medicare SNPs that are intended to provide more integrated care for dual eligibles.
■ Revisit the clawback requirement. Because a number of states imple-

mented cost containment measures in fiscal year 2003 but did not realize Medicaid savings until fiscal years 2004 or 2005, the choice of
2003 as the baseline year adds to the cost burden on states. In addition, the clawback payment requirement may have the unintended
consequence of acting as a disincentive for states to exercise the option of providing full Medicaid benefits to aged and disabled individuals with incomes up to 100 percent of the FPL.

ENDNOTES
1. The Centers for Medicare & Medicaid Services uses the term “limited income subsidy”
when referring to this provision.
2. Beneficiaries with incomes below 100 percent of the federal poverty level (FPL) will
have no monthly premium, no annual deductible, limited co-payments, and no “donut
hole”—the gap in coverage when drug costs exceed a certain annual figure. Persons with
incomes between 100 and 135 percent of the FPL have the same benefit package but slightly
higher co-payments. Those with incomes between 135 and 150 percent of the FPL are entitled to a partial premium subsidy and are not subject to the donut hole, but must pay an
annual deductible and 15 percent of drug costs up to an annual figure. Eligible nursing
home residents will receive the full premium subsidy and will not be subject to the donut
hole or the annual deductibles and co-payments.
3. See Judith D. Moore and Jennifer Ryan, “Implementing the New Medicare Drug Benefit:
Challenges and Opportunities for States,” National Health Policy Forum, Meeting Report,
August 31, 2004; available at www.nhpf.org/pdfs_other/MMAMtgRpt(07-22-04).pdf.
4. A Medicare Savings Program is one of the three benefits currently available to limited
income Medicare beneficiaries who do not qualify for full Medicaid benefits in their state.
The Qualified Medicare Beneficiary (QMB) program is open to persons with incomes up to
Endnotes / continued ➤
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Endnotes / continued
100 percent of the FPL; Medicaid will pay their Part B premium, Part A premium (if any),
and Medicare deductibles and co-payments. The Specified Low Income Medicare Beneficiary (SLMB) program reaches individuals with incomes between 100 and 120 percent of
the FPL; Medicaid pays only the Part B deductible for them. Both the QMB and SLMB
programs are entitlement programs, meaning the state must enroll all applicants who meet
the income and assets tests. The third program is the Qualifying Individual (QI) program,
available to Medicare beneficiaries with incomes between 120 and 135 percent of the FPL.
Under this program the state pays a portion of the Part B premium on behalf of the beneficiary. States can cap enrollment in the QI program.
5. The drug discount card program was also authorized under the MMA for 2004 and
2005 has even easier requirements to qualify for cash assistance in paying for prescription
drugs. But despite vigorous federal, state, and advocacy group efforts, the program has
yielded a disappointingly low enrollment rate.
6. Late enrollees will pay a higher premium of 1 percent per month of delay. For those
with incomes below 135 percent of the FPL, the federal government will partially subsidize the penalty’s cost.
7. Both LIS and state MSP eligibility criteria begin with the SSI eligibility rules. The LIS
rules then deviate somewhat, principally through higher asset ceilings. State rules can vary
with regard to both income and assets. See the June 2005 CMS state-by-state comparison of
state MSP and SSI eligibility rules for more information, available at www.cms.hhs.gov/
medicarereform/states/msp_charts.pdf.
8. See James M. Verdier and Myong Kim, “Medicaid Drug Use Data Show High Costs
and Wide Variation for Dual Eligibles,” Mathematica Policy Research, Inc., Issue Brief,
Number 5, August 2005; available at www.mathematica-mpr.com/publications/PDFs/
medicaiddata.pdf.
9. The clawback payments for 2006 are based on state prescription drug expenditures
per full dual eligible for 2003, adjusted by the estimated average annual percent change
in national per capita prescription drug expenditures for 2004, 2005, and 2006, including
both Medicaid and private prescription drug expenditures. This growth factor will capture both Medicaid and private-sector cost and utilization trends between 2003 and 2006,
not just Medicaid-specific or state-specific trends.

The National Health Policy Forum is a nonpartisan research and public
policy organization at The George Washington University. All of its
publications since 1998 are available online at www.nhpf.org.
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APPENDIX 1 — Agenda for July 12, 2005 Meeting
“Implementing the New Medicare Drug Benefit: Continuing Challenges for States”
10:00 am

Welcome

Judith D. Moore, Senior Fellow, National Health Policy Forum
10:15 am

OVERVIEW OF DUAL ELIGIBLES AND RELATED BENEFICIARIES

James M. Verdier, JD, Senior Fellow, Mathematica Policy Research, Inc.
STATUS REPORT FROM STATES

Carol A. Herrmann, Commissioner, Alabama State Medicaid Agency
Carolyn Ingram, Director, Medical Assistance Division, New Mexico
Department of Human Services
Michael Fogarty, JD, Chief Executive Officer, Oklahoma Health Care Authority
FEDERAL PERSPECTIVE

Gale Arden, Director, Disabled and Elderly Health Programs Group, Center for Medicaid
and State Operations, Centers for Medicare & Medicaid Services
HEALTH PLAN AND BENEFICIARY PERSPECTIVE

Karen Davenport, Washington Director, Medicare Rights Center
Katherine H. Metzger, Director, Medicare and Medicaid Programs,
Fallon Community Health Plan
11:00 am

A CLOSER LOOK

All Panelists
■

Eligibility, outreach and process issues

■

Enrollment issues

■

Care management issues

12:30 pm

Lunch

1:15 pm

OTHER MAJOR CHALLENGES: MESHING DATA SYSTEMS AND STATE FINANCING ISSUES

Charles Milligan, JD, Executive Director, Center for Health Program Development and
Management, University of Maryland, Baltimore County
All Panelists
2:00 pm

WRAP-UP AND CLOSING COMMENTS

Judith D. Moore
All Panelists
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APPENDIX 2 — Expert Panelists and Meeting Participants

Expert Panelists
Gale Arden
Director, Disabled and Elderly
Health Programs Group
Center for Medicaid and
State Operations
Centers for Medicare &
Medicaid Services
Department of Health and
Human Services
Karen Davenport
Washington Director
Medicare Rights Center

Carol A. Herrmann
Commissioner
Alabama Medicaid Agency
Carolyn Ingram
Director, Medical Assistance Division
New Mexico Department of
Human Services
Katherine H. Metgzer
Director, Medicare and
Medicaid Programs
Fallon Community Health Plan

Charles Milligan, JD
Executive Director
Center for Health Program
Development and Management
University of Maryland,
Baltimore County
Lee Partridge
Consultant
James M. Verdier, JD
Senior Fellow
Mathematica Policy Research, Inc.

Michael Fogarty, JD
Chief Executive Officer
Oklahoma Health Care Authority

Meeting Participants
Rhoda Abrams
Associate Adjunct Professor
Johns Hopkins University
Melissa Atkinson
Health Policy Advisor (R)
Senate Committee on Finance
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U.S. Congressional Budget Office

Charlene Brown
Deputy Chief of Operations
Centers for Medicare &
Medicaid Services
Department of Health and
Human Services

Alissa Deboy
Special Assistant
Center for Beneficiary Choices
Centers for Medicare &
Medicaid Services
Department of Health and
Human Services

Jim Cantwell
Budget Analyst (R)
Committee on the Budget
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U.S. Senate
Sean Donohue
Senior Policy Advisor
Office of Sen. James Jeffords
U.S. Senate
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APPENDIX 2 — Meeting Participants (continued)
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